



## FOR IMMEDIATE RELEASE

April 30, 2026

Listed Company Name: Eisai Co., Ltd.  
Representative: Haruo Naito  
Representative Corporate  
Officer and CEO  
Securities Code: 4523  
Stock Exchange Listings: Prime Market of the Tokyo  
Stock Exchange  
Inquiries: Teruyuki Masaka  
Vice President,  
Corporate Communications  
Phone +81-3-3817-5120

### Revenue of LEQEMBI® (Preliminary Basis)

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI®" (generic name: lecanemab) was JPY 88.0 billion for the fiscal year 2025 (April 1, 2025 – March 31, 2026). By major markets, revenue came to JPY 44.6 billion in the United States, JPY 24.4 billion in Japan, and JPY 12.4 billion in China.

This information is being disclosed in conjunction with the announcement of the financial results for the first quarter of 2026 by Biogen Inc. (Headquarters: Cambridge, Massachusetts) on April 29, 2026. Eisai's financial results for the fiscal year 2025, including details of LEQEMBI's revenue, will be disclosed in Eisai's financial disclosure scheduled for May 15, 2026.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.

\*\*\*